Status:
COMPLETED
eHealth Intervention for Medication Adherence in Breast Cancer Survivors
Lead Sponsor:
Luxembourg Institute of Health
Collaborating Sponsors:
Centre Hospitalier du Luxembourg
Centre Hospitalier Emile Mayrisch
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Tamoxifen and aromatase inhibitors are two oral hormonal therapies (OHT) that decrease the risk of breast cancer recurrence by over 30 %. Their efficacy however strongly depends on the duration of use...
Eligibility Criteria
Inclusion
- Signed informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Female aged ≥18 years old
- 1st prescription of adjuvant treatment (Nolvadex, Arimidex)
- Treated in either the Centre Hospitalier du Luxembourg (CHL) or Centre Hospitalier Emile Mayrisch (CHEM)
- Luxembourg resident
- Fluent in French and/or German
- Outpatient
- Possession of a smart-phone (iOS, Android)
Exclusion
- Male
- In situ or metastatic tumors
- Follow-up treatment outside of CHL or CHEM
- Non-Luxembourgish residents
- Inpatient
Key Trial Info
Start Date :
October 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2022
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT05324020
Start Date
October 4 2021
End Date
November 30 2022
Last Update
September 7 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Emile Mayrisch (CHEM)
Esch-sur-Alzette, Luxembourg, L-4240
2
Centre Hospitalier de Luxembourg (CHL)
Luxembourg, Luxembourg, L-1210